Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to two newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards are non-qualified stock options for an aggregate of 57,500 shares, 10-year term, exercise price $25.66 per share.
Options vest 25% after one year then monthly over 36 months and are governed by the 2022 Inducement Plan and individual option agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – DMRA
-1.17%
-1.17%Session close to close
In the May 1 session, DMRA declined 1.17%, reflecting a mild negative market reaction.
This announcement details additional equity inducement grants—57,500 options at an exercise price of...
Analysis
This announcement details additional equity inducement grants—57,500 options at an exercise price of $25.66 with a 10-year term—under Damora’s 2022 Inducement Plan. It follows earlier inducement awards and leadership changes in March 2026. Investors tracking dilution and governance may compare these grants with prior awards and the company’s full-year 2025 financials, including a cash balance of about $535M and a net loss of $209.8M.
Key Figures
Inducement options:57,500 sharesExercise price:$25.66 per shareOption term:10 years+5 more
8 metrics
Inducement options57,500 sharesAggregate non-qualified stock options granted to two new hires
Exercise price$25.66 per shareStrike price for new inducement stock options
Option term10 yearsDuration of newly granted inducement stock options
Cash balance$535 millionCash as of February 28, 2026 from full-year 2025 results
Net loss 2025$209.8MFull-year 2025 net loss driven by acquired in-process R&D charge
R&D expense 2025$26.9MFull-year 2025 research and development spending
G&A expense 2025$9.7MFull-year 2025 general and administrative expenses
Short interest2.01% of floatReported short interest level in risk context
Reported 2025 financials, cash position, and development timelines for DMR-001.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has produced mixed reactions: strong gains on leadership changes, while earnings and some inducement grants saw negative moves.
Recent Company History
Over recent months, Damora reported full-year 2025 results, executed leadership changes, and repeatedly used equity inducement grants tied to hires. Earnings on Mar 19, 2026 coincided with a -5.52% move, while the CEO and board appointments on Mar 23, 2026 saw a strong 27.07% gain. Inducement grants on Mar 30, 2026 preceded a -4.82% reaction. Today’s new employee-focused grants continue that compensation pattern.
"The inducement grants were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"The inducement grants consist of non-qualified stock options to purchase an aggregate of 57,500 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
stock option agreementfinancial
"subject to the terms and conditions of ... and the terms and conditions of a stock option agreement."
A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to two newly-hired, non-executive employees. The inducement grants were approved by Damora’s independent Compensation Committee and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 57,500 shares of the Damora’s common stock with a 10-year term and an exercise price of $25.66 per share. The options vest as to 25% on the first anniversary of the applicable grant date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a stock option agreement.
About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
What did Damora Therapeutics (DMRA) announce on May 1, 2026 about inducement grants?
Damora granted non-qualified stock options totaling 57,500 shares to two newly hired non-executive employees. According to Damora, the options have a 10-year term, a $25.66 exercise price, and vest 25% after one year then monthly over 36 months.
How do the DMRA inducement option vesting terms work for the new hires?
The options vest 25% on the first anniversary of the grant date, then vest in equal monthly installments over the following 36 months. According to Damora, this schedule applies to the aggregate 57,500-share award under the inducement plan.
What is the exercise price and term for Damora Therapeutics' (DMRA) inducement options?
The exercise price is $25.66 per share and each option has a 10-year term from grant. According to Damora, the awards are non-qualified stock options issued under the 2022 Inducement Plan and subject to option agreements.
Are Damora's (DMRA) inducement grants approved by an independent committee?
Yes. According to Damora, the independent Compensation Committee approved the inducement grants as material inducements under Nasdaq Listing Rule 5635(c)(4). The grants were made to secure the hires and are governed by the company's inducement plan and option agreements.
Will Damora Therapeutics (DMRA) disclose further details about these inducement grants?
Damora indicated the grants are subject to the 2022 Inducement Plan and stock option agreements, implying standard disclosure for equity awards. According to Damora, further specifics would follow in filings or company disclosures as required under Nasdaq rules.
